Affinage

DLX2

Homeobox protein DLX-2 · UniProt Q07687

Length
328 aa
Mass
34.2 kDa
Annotated
2026-04-28
94 papers in source corpus 35 papers cited in narrative 36 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

DLX2 is a homeodomain transcription factor that functions as a master regulator of cell fate decisions in the developing forebrain, retina, branchial arch ectomesenchyme, and skeletal lineages. It acts as a pioneer factor by forming a complex with LAP2α through a 38-amino-acid homeodomain motif to remodel chromatin and activate pro-ectomesenchymal gene networks (PMID:41533791), and it directly binds and transactivates targets including Arx, TrkB, Brn3b, Gad1/2, Vgat, Osteocalcin, Alp, WNT1, and Msx2 while repressing TGFβRII and MMP13 (PMID:18923043, PMID:18086710, PMID:28356311, PMID:29028947, PMID:30880332, PMID:21897365, PMID:29787757). In the forebrain, DLX2 is essential for GABAergic interneuron differentiation, migration, and synaptic function, and it determines the neuron-versus-oligodendrocyte fate choice by repressing Olig2-dependent oligodendrocyte precursor formation (PMID:9247261, PMID:17678855, PMID:33574458). In cancer contexts, DLX2 bypasses cellular senescence by destabilizing the TTI1/TTI2/TEL2 complex to suppress ATM-p53 signaling and promotes epithelial-mesenchymal transition through Snail induction and glutamine metabolism reprogramming (PMID:26833729, PMID:25651912, PMID:26771232).

Mechanistic history

Synthesis pass · year-by-year structured walk · 17 steps
  1. 1995 High

    Establishing that DLX2 is required for both forebrain differentiation and branchial arch skeletal patterning answered the foundational question of where and when this transcription factor acts during embryogenesis.

    Evidence Dlx-2 null mice showing abnormal forebrain and respecified cranial neural crest fate

    PMID:7590232

    Open questions at the time
    • Downstream transcriptional targets unknown
    • Mechanism of cell fate respecification undefined
    • Redundancy with Dlx-1 not yet dissected
  2. 1997 High

    Systematic analysis of Dlx-1, Dlx-2, and double-knockout mice revealed that DLX1/2 have overlapping roles in striatal neurogenesis, branchial arch patterning, odontogenic specification, and cell cycle exit, clarifying the cooperative logic of the Dlx gene family.

    Evidence Dlx-1/2 single and double-KO mice with skeletal, striatal, and dental phenotypes; tissue recombination experiments; antisense knockdown in basal ganglia cultures

    PMID:9187081 PMID:9188040 PMID:9247261 PMID:9428417

    Open questions at the time
    • Direct transcriptional targets of DLX2 not identified
    • Whether DLX2 acts as activator or repressor unknown
    • Signaling pathways upstream of DLX2 in these contexts undefined
  3. 2000 High

    Identification of BMP4 and FGF8 as upstream regulators maintaining distinct epithelial and mesenchymal DLX2 expression domains in the branchial arch placed DLX2 downstream of key morphogenetic signaling pathways.

    Evidence Transgenic lacZ reporters with BMP4/FGF8 bead implantation in mouse mandibular arch

    PMID:10603340

    Open questions at the time
    • Whether BMP/FGF regulate DLX2 directly or indirectly unresolved
    • Cis-regulatory elements mediating this regulation not mapped
  4. 2001 Medium

    Placing DLX2 downstream of BMP-2/Smad signaling in chondroblasts and demonstrating PITX2/Msx2 competition at the DLX2 promoter defined the transcriptional regulatory logic controlling DLX2 expression in skeletal and dental contexts.

    Evidence Antisense and dominant-negative Smad1 blocking BMP-2-induced Col2α1 enhancer activity; EMSA and luciferase reporters for PITX2/Msx2 binding to DLX2 promoter

    PMID:11445007 PMID:11763998

    Open questions at the time
    • In vivo validation of PITX2-DLX2 regulatory axis lacking
    • Whether DLX2 directly binds Col2α1 enhancer not shown
  5. 2004 High

    Demonstrating that Dlx1/2 are required for late-born retinal ganglion cell survival extended the known developmental roles of DLX2 beyond forebrain and craniofacial tissues to the retina.

    Evidence Dlx1/2 double-KO retinal analysis showing RGC apoptosis and optic nerve thinning

    PMID:15604100

    Open questions at the time
    • Direct transcriptional targets of DLX2 in retina unknown
    • Whether DLX2 acts cell-autonomously in RGCs not established
  6. 2006 High

    Discovery that the lncRNA Evf-2 forms a complex with DLX2 to coactivate the Dlx-5/6 enhancer, and that DLX2 synergizes with Lef-1 to activate Msx2, revealed two distinct modes of DLX2 transcriptional co-regulation — one RNA-dependent and one protein-protein dependent.

    Evidence Co-IP of Evf-2/DLX2 complex and enhancer reporter assays; ChIP and reciprocal Co-IP of DLX2-Lef-1 with Msx2 promoter activation

    PMID:16705037 PMID:17068080

    Open questions at the time
    • Structural basis of Evf-2/DLX2 interaction unknown
    • Whether Evf-2 coactivation applies to targets beyond Dlx-5/6 enhancer untested
    • Genome-wide DLX2-Lef-1 co-occupancy not mapped
  7. 2007 High

    Establishing that DLX1/2 control the neuron-versus-oligodendrocyte fate decision by repressing Olig2-dependent OPC formation, and identifying TrkB as a direct DLX2 transcriptional target in retina, revealed DLX2 as a binary fate switch and defined its first direct target genes.

    Evidence Dlx1/2 conditional KO with OPC transplantation into wild-type brain; ChIP and gain/loss-of-function for DLX2 at TrkB promoter in retina

    PMID:17678855 PMID:18086710

    Open questions at the time
    • Whether DLX2 directly binds Olig2 regulatory elements unknown
    • Mechanism by which DLX2 represses oligodendroglial fate not molecularly defined
  8. 2008 High

    Identification of Arx as a direct DLX2 target mediating interneuron migration, and demonstration that DLX2 is necessary and sufficient for olfactory bulb interneuron neurogenesis with Pax6-dependent dopaminergic subtype specification, mapped the downstream transcriptional cascade controlling GABAergic interneuron diversification.

    Evidence Enhancer isolation and genetic epistasis for Arx; retroviral gain/loss-of-function for DLX2 in adult SVZ with Pax6 conditional deletion

    PMID:18562615 PMID:18923043

    Open questions at the time
    • Whether DLX2 directly interacts with Pax6 protein unknown
    • Full set of DLX2-regulated enhancers in interneurons not cataloged
  9. 2011 High

    Demonstrating that DLX2 directly represses TGFβRII to block TGFβ-induced growth arrest and apoptosis while inducing betacellulin/EGFR signaling revealed a pro-oncogenic mechanism through which a developmental transcription factor subverts growth control.

    Evidence DLX2 overexpression/knockdown in mammary epithelial cells with in vivo tumor and metastasis assays

    PMID:21897365

    Open questions at the time
    • Whether TGFβRII repression involves direct DLX2 binding to promoter (ChIP) not shown in this study
    • Relevance to human cancer in vivo not validated
  10. 2012 High

    Establishing that the Rb/E2F pathway directly controls DLX2 expression by binding the I12b forebrain enhancer and proximal promoter linked DLX2 to cell cycle regulation and explained how Rb deficiency leads to interneuron loss.

    Evidence ChIP for E2F binding in vitro and in vivo; Rb-deficient mouse brain with interneuron phenotyping

    PMID:22699903

    Open questions at the time
    • Which specific E2F family members are activating versus repressing DLX2 unclear
    • Whether E2F-DLX2 axis operates outside the forebrain unknown
  11. 2015 Medium

    Linking DLX2 to TGFβ/Wnt-induced EMT via Snail activation and metabolic reprogramming (glycolytic switch, GLS1-dependent glutamine metabolism) expanded the oncogenic function of DLX2 beyond growth control to include metabolic and migratory programs.

    Evidence shRNA knockdown and overexpression in cancer cell lines; GLS1 epistasis with in vivo metastasis assays

    PMID:25651912 PMID:26771232

    Open questions at the time
    • Direct binding of DLX2 to Snail or GLS1 promoters not demonstrated by ChIP
    • Whether metabolic reprogramming is relevant to normal DLX2 developmental functions unknown
  12. 2016 Medium

    Discovery that DLX2 bypasses senescence by destabilizing the TTI1/TTI2/TEL2 complex to suppress ATM-p53 signaling provided a specific molecular mechanism for DLX2's oncogenic role distinct from its TGFβRII repression.

    Evidence Gain-of-function senescence bypass screen; Western blot for TTI1/TTI2/TEL2 complex

    PMID:26833729

    Open questions at the time
    • Whether DLX2 transcriptionally represses TTI1/TTI2/TEL2 components or acts post-transcriptionally unresolved
    • Not independently confirmed
  13. 2017 High

    Triple-KO genetic epistasis demonstrated that DLX1/2 directly activate Brn3b to specify retinal ganglion cells, and that miR-185-5p targets DLX2 for suppression in skeletal lineages, revealing both a downstream effector in the retina and a post-transcriptional regulatory mechanism.

    Evidence Dlx1/Dlx2/Brn3b triple-KO with near-total RGC loss; dual-luciferase reporter confirming miR-185-5p targeting of DLX2 3'-UTR

    PMID:28356311 PMID:29242628

    Open questions at the time
    • Whether Brn3b is sufficient to rescue RGC loss in Dlx1/2 mutants untested
    • Full spectrum of miRNAs regulating DLX2 not surveyed
  14. 2018 High

    Conditional knockout studies in cortical interneurons established that DLX1/2 directly drive GABAergic synaptic gene expression (Gad1, Gad2, Vgat) and are required for normal inhibitory synaptic transmission, and ChIP identified DLX2 binding at the MMP13 promoter to repress chondrocyte hypertrophy, expanding the catalog of direct targets across tissues.

    Evidence Conditional Dlx1/2 KO with mIPSC recordings and ChIP-seq/reporters; ChIP and luciferase for MMP13 in chondroblasts

    PMID:29028947 PMID:29787757

    Open questions at the time
    • Genome-wide DLX2 cistrome in interneurons not fully characterized
    • Whether MMP13 repression is relevant in vivo during skeletal development unknown
  15. 2019 High

    ChIP and mutagenesis demonstrated that DLX2 directly transactivates Osteocalcin and Alp promoters to enhance bone formation independently of Runx2 and Osterix, establishing a direct osteogenic transcriptional program.

    Evidence ChIP, site-directed mutagenesis, luciferase reporters in BMSCs/MC3T3-E1 cells; in vivo implantation

    PMID:30880332

    Open questions at the time
    • Whether DLX2 cooperates with other osteogenic factors at these promoters untested
    • Physiological requirement for DLX2 in adult bone homeostasis unknown
  16. 2021 High

    Demonstrating that DLX2 alone is sufficient to reprogram postnatal OPCs into functional GABAergic neurons within days confirmed DLX2 as a dominant determinant of the neuron-oligodendrocyte binary fate switch and opened therapeutic reprogramming possibilities.

    Evidence DLX2 misexpression in postnatal OPCs with electrophysiology and transcriptomics

    PMID:33574458

    Open questions at the time
    • Long-term stability and integration of reprogrammed neurons not established
    • Whether DLX2-reprogrammed neurons are functionally equivalent to endogenous interneurons unknown
  17. 2025 High

    Identification of DLX2 as a pioneer transcription factor that complexes with LAP2α via a 38-amino-acid homeodomain motif to remodel chromatin and activate ectomesenchymal gene networks fundamentally redefined the mechanism by which DLX2 accesses its target genes.

    Evidence Co-IP, domain mutagenesis, CUT&Tag chromatin profiling, ESC differentiation assays

    PMID:41533791

    Open questions at the time
    • Whether LAP2α interaction is required for DLX2 pioneer activity in neural contexts untested
    • Structural basis of DLX2-nucleosome interaction unresolved
    • Whether all DLX2 targets require pioneer activity unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • A comprehensive genome-wide DLX2 cistrome across developmental contexts, the structural basis of DLX2 pioneer activity and LAP2α interaction, and the relevance of DLX2's oncogenic mechanisms (TTI1/TTI2/TEL2, metabolic reprogramming) to normal physiology remain to be established.
  • No genome-wide DLX2 binding map across multiple tissues and developmental stages
  • No crystal or cryo-EM structure of DLX2 bound to nucleosome or LAP2α
  • Whether DLX2 pioneer activity is relevant in the forebrain or retina not tested

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 11 GO:0003677 DNA binding 7 GO:0003723 RNA binding 1
Localization
GO:0005634 nucleus 4 GO:0005694 chromosome 1
Pathway
R-HSA-74160 Gene expression (Transcription) 11 R-HSA-1266738 Developmental Biology 10 R-HSA-112316 Neuronal System 6 R-HSA-162582 Signal Transduction 5 R-HSA-4839726 Chromatin organization 1
Partners
LAP2ALEF1MSX2PAX6PITX2SMAD1
Complex memberships
DLX2-Evf-2 lncRNA coactivator complexDLX2-LAP2α chromatin remodeling complex

Evidence

Reading pass · 36 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2006 The noncoding RNA Evf-2 (transcribed from the Dlx-5/6 ultraconserved region) forms a stable in vivo complex with DLX2 protein and acts as a transcriptional coactivator, specifically increasing DLX2-mediated transcriptional activity at the Dlx-5/6 enhancer in a target- and homeodomain-specific manner. Co-immunoprecipitation of Evf-2 ncRNA and DLX2 protein in vivo; luciferase enhancer reporter assays; neural explant treatment with Sonic hedgehog Genes & development High 16705037
1997 Mice lacking both Dlx-1 and Dlx-2 show a time-dependent block in striatal differentiation: early-born neurons migrate to form a striosome-enriched region, but later-born neurons accumulate in the proliferative zone, establishing that Dlx-1/2 are required for development of the striatal subventricular zone and differentiation of late-born striatal matrix neurons. Targeted null mutations of Dlx-1 and Dlx-2 in mice; histological and marker analysis of striatal development Neuron High 9247261
1995 Dlx-2 null mutation in mice causes abnormal forebrain differentiation and respecification of cranial neural crest cell fate, resulting in abnormal morphogenesis of proximal first and second branchial arch skeletal derivatives, demonstrating Dlx-2 controls both branchial arch and forebrain development. Gene targeting to generate Dlx-2 null mice; skeletal and histological analysis Genes & development High 7590232
1997 Dlx-1 and Dlx-2 are required for proximodistal patterning of the branchial arches; Dlx-1/2 double mutants uniquely lack maxillary molars, demonstrating overlapping and distinct roles in craniofacial skeletal patterning. Targeted null mutations of Dlx-1, Dlx-2, and Dlx-1/2 double knockout mice; skeletal and soft tissue analysis Developmental biology High 9187081
1997 Dlx-1 and Dlx-2 specify maxillary molar ectomesenchyme as odontogenic; loss of both genes causes the molar ectomesenchyme to lose odontogenic potential and switch fate to chondrogenic, as shown by heterologous recombination between mutant and wild-type epithelium/mesenchyme and marker analysis. Dlx-1/2 double-KO mice; heterologous tissue recombination; molecular marker analysis (Barx1, Sox9) Development (Cambridge, England) High 9428417
2007 Dlx1 and Dlx2 repress oligodendrocyte precursor cell (OPC) formation in the ventral telencephalon by acting on a common progenitor to determine neuronal versus oligodendroglial cell fate; Dlx1/2 negatively regulate Olig2-dependent OPC formation, and progenitors from Dlx1/2 mutant telencephalon differentiate into myelinating oligodendrocytes rather than neurons when transplanted. Dlx1/2 conditional KO mice; progenitor transplantation into wild-type mice; fate mapping Neuron High 17678855
2008 Dlx2 directly activates Arx transcription through a GABAergic enhancer element containing Dlx-binding sites; Dlx overexpression induces ectopic Arx expression and its isolated enhancer, while loss of Dlx reduces Arx expression. Arx mediates Dlx-dependent promotion of interneuron migration but not GABAergic cell fate commitment. Enhancer isolation and functional characterization; Dlx gain-of-function in Arx mutant tissue; loss-of-function in Dlx mutant tissue; genetic epistasis The Journal of neuroscience High 18923043
2008 Dlx2 is necessary and sufficient for neurogenesis of virtually all OB interneurons from the lateral subependymal zone in adults, and promotes specification of periglomerular neurons toward a dopaminergic fate; this PGN subtype specification requires interaction with Pax6, as Pax6 deletion blocks Dlx2-mediated PGN specification. Retroviral vectors for cell-autonomous Dlx2 gain- and loss-of-function in adult brain; Pax6 conditional deletion; immunofluorescence The Journal of neuroscience High 18562615
2001 PITX2 directly binds bicoid-like elements in the Dlx2 promoter and activates Dlx2 transcription ~45-fold; Msx2 competes with PITX2 for binding to the same bicoid element and represses Dlx2 promoter activity; coexpression of PITX2 and Msx2 results in transcriptional antagonism at the Dlx2 promoter. Luciferase reporter assays; EMSA; co-expression in CHO and LS-8 tooth epithelial cell lines Gene expression Medium 11763998
2001 BMP-2 signaling to the Col2alpha1 chondrocyte-specific enhancer requires Dlx-2; rBMP-2 upregulates Dlx-2 expression in chondroblasts at an early differentiation stage, and blocking Dlx-2 with antisense oligonucleotides or dominant-negative Smad1 abolishes BMP-2-stimulated Col2alpha1 enhancer activity, placing Dlx-2 downstream of BMP-2/Smad signaling in chondroblasts. Antisense oligonucleotides against Dlx-2; dominant-negative Smad1 expression; luciferase Col2alpha1 enhancer reporter; rBMP-2 treatment of TMC23 chondroblasts DNA and cell biology Medium 11445007
2006 DLX2 activates the Msx2 promoter and binds its DNA as a monomer and dimer; Lef-1 physically interacts with DLX2 (confirmed by Co-IP and pull-down), and co-expression of DLX2 with Lef-1 isoforms synergistically activates the Msx2 promoter; Msx2 can auto-regulate its own promoter and repress DLX2 activation in a dose-specific manner; ChIP confirmed Msx2 as a downstream target of DLX2 and Lef-1. ChIP assay; Co-immunoprecipitation; protein pull-down; luciferase reporter assays; deletion analysis Nucleic acids research High 17068080
2011 DLX2 acts as a direct transcriptional repressor of TGFβ receptor II (TGFβRII) gene expression, reducing canonical Smad-dependent TGFβ signaling and p21CIP1 expression while increasing c-Myc; DLX2 also directly induces betacellulin expression to promote cell survival via EGF receptor signaling, thereby counteracting TGFβ-induced cell-cycle arrest and apoptosis. Dlx2 overexpression and knockdown in mammary epithelial cells; Western blot for pathway components; reporter assays; in vivo tumor and metastasis assays The EMBO journal High 21897365
2016 DLX2 expression reduces the TTI1/TTI2/TEL2 complex (required for ATM stabilization), leading to reduced ATM-p53 signaling and senescence bypass; DLX2 overexpression extends replicative lifespan through this mechanism. Gain-of-function senescence bypass screen; Western blot for TTI1/TTI2/TEL2 complex components; ATM-p53 pathway analysis Genes & development Medium 26833729
2015 Dlx-2 is induced by TGF-β and Wnt signaling and mediates TGF-β/Wnt-induced EMT and glycolytic switch through transcriptional activation of Snail; Dlx-2/Snail signaling also suppresses cytochrome c oxidase (COX) subunits including COXVIc, linking Dlx-2 to mitochondrial repression. shRNA knockdown; overexpression; RT-PCR; Western blot in cancer cell lines International journal of oncology Medium 25651912
2016 Dlx-2 induces glutaminase (GLS1) expression in a TGF-β/Wnt-dependent manner; GLS1-mediated glutamine metabolism is required for Dlx-2-, TGF-β-, and Wnt-induced EMT and glycolytic switch; Dlx-2 and GLS1 maintain Snail mRNA levels by suppressing p53-dependent Snail-targeting microRNAs. shRNA knockdown of GLS1 and Dlx-2; glutamine deprivation; pharmacological inhibitors; in vivo metastasis assays Oncotarget Medium 26771232
2019 DLX2 directly binds Dlx2-response cis-acting elements in the Osteocalcin (OCN) and Alp promoters to transactivate their expression, enhancing osteogenic differentiation and bone formation without affecting Runx2, Dlx5, Msx2, or Osterix levels. Chromatin immunoprecipitation (ChIP); site-directed mutagenesis; luciferase reporter assays; DLX2 overexpression in BMSCs and MC3T3-E1 cells; in vivo implantation in nude mice International journal of oral science High 30880332
2018 DLX2 directly drives Gad1, Gad2, and Vgat expression in cortical interneurons (CINs), as conditional Dlx1/2 knockouts show reduced mIPSC amplitude, fewer GABAergic synapses on excitatory neurons, and hypoplastic dendrites; Dlx1/2 also regulate GRIN2B expression. Conditional KO of Dlx1, Dlx2, Dlx1&2; electrophysiology (mIPSC recordings); ChIP-seq/reporter assays for direct transcriptional targets; immunostaining Cerebral cortex High 29028947
2004 Dlx1 and Dlx2 are required for terminal differentiation and survival of late-born retinal ganglion cells (RGCs); Dlx1/2 null retinas show reduced GCL with increased RGC apoptosis, thinning of the optic nerve, and ectopic Crx expression in GCL, while early-born RGCs and amacrine/horizontal cells are largely unaffected. Dlx1/2 double-KO mice; histological and TUNEL analysis; marker analysis Development (Cambridge, England) High 15604100
2007 DLX2 directly binds a specific region of the TrkB promoter in retinal neuroepithelium during embryogenesis; ectopic Dlx2 expression in retinal explants activates TrkB expression, and Dlx2 knockdown in primary retinal cultures reduces TrkB expression, establishing TrkB as a direct Dlx2 transcriptional target required for RGC survival. ChIP assay; luciferase reporter assays; in vitro gain/loss-of-function in retinal explants and primary cultures Nucleic acids research High 18086710
2017 DLX1 and DLX2 function as direct transcriptional activators of Brn3b expression in the developing retina; Dlx2 knockdown in primary embryonic retinal cultures reduces Brn3b expression, and Dlx2 gain-of-function in utero increases Brn3b expression; Dlx1/2/Brn3b triple-KO shows near-total RGC loss with increased amacrine cells. Triple-KO mice (Dlx1/Dlx2/Brn3b); in utero electroporation for gain-of-function; primary retinal culture knockdown; ChIP/reporter assays Development (Cambridge, England) High 28356311
2012 The Rb/E2F pathway directly controls Dlx1 and Dlx2 expression: repressor E2Fs bind Dlx forebrain-specific enhancer I12b and Dlx1/Dlx2 proximal promoter regions, and Rb deficiency results in dramatic reduction of Dlx1 and Dlx2 expression, loss of interneuron subtypes, and severe migration defects. ChIP assay in vitro and in vivo; Rb-deficient mouse brain analysis; E2F reporter assays; interneuron subtype marker analysis The Journal of neuroscience High 22699903
2005 Dlx2 overexpression in neural tube (via in ovo electroporation) inhibits neural crest cell migration and induces N-cadherin and NCAM upregulation in branchial arch mesenchyme, causing increased cell-cell adhesion and mesenchymal condensation, suggesting Dlx2 regulates ectomesenchymal cell adhesion. In ovo electroporation of chick embryos; immunostaining for N-cadherin and NCAM; cell aggregation assays Developmental biology Medium 15848386
2002 Dlx2-expressing subpallial cells migrate ventrodorsally from the ganglionic eminences and give rise to astrocytes and oligodendrocytes in the white matter and cerebral cortex, as demonstrated by short-term lineage tracing using a Dlx2/tauLacZ knock-in. Dlx2/tauLacZ knock-in lineage tracing; immunohistochemistry for glial markers (Zebrin II); histological analysis The Journal of neuroscience High 12427838
2009 DLX2 promotes the lineage transition from neural stem cells (NSCs) to transit-amplifying precursors (TAPs) in the postnatal SVZ, and also enhances the proliferative response of neuronal progenitors to EGF, demonstrating that DLX2 and EGFR signaling interact at multiple levels to coordinate SVZ progenitor proliferation. Forced DLX2 expression in SVZ-isolated NSCs; in vitro EGF response assays; in vivo modulation of DLX2 Molecular and cellular neurosciences Medium 19683576
2008 I12b and URE2, two ultra-conserved DNA elements near the Dlx1/2 locus, are direct transcriptional targets of DLX2 in vivo; their proper activity requires Dlx1 and Dlx2 expression, as shown by Cre-mediated fate mapping and transgenic reporter analysis. Transgenic Cre-reporter mice; fate mapping; analysis in Dlx1/2 mutant background Molecular and cellular neurosciences Medium 19026749
2021 Misexpression of Dlx2 alone in postnatal mouse OPCs is sufficient to switch their fate to GABAergic neurons within 2 days by downregulating Olig2 and upregulating a network of inhibitory neuron transcripts; after two weeks, some OPC-derived neurons generate trains of action potentials and form clusters of GABAergic synaptic proteins. Dlx2 misexpression in postnatal OPCs; immunostaining; electrophysiology; transcriptomic analysis Scientific reports High 33574458
2000 Epithelial expression of Dlx2 in the first branchial arch is regulated by BMP4 (planar signaling within distal oral epithelium), while mesenchymal expression is regulated by FGF8 (from overlying epithelium); FGF8 also inhibits epithelial Dlx2 expression through a signaling pathway requiring the mesenchyme, establishing that BMP4 and FGF8 maintain distinct epithelial and mesenchymal Dlx2 expression domains. Transgenic lacZ reporter constructs; bead implantation for BMP4/FGF8 signaling; in situ hybridization Development (Cambridge, England) High 10603340
2016 Radiation-induced DLX2 expression is dependent on Smad2/3 signaling; knockdown of Smad2/3 abrogates radiation-induced DLX2 upregulation, and DLX2 in turn promotes radioresistance and EMT in cancer cell lines. siRNA knockdown of Smad2/3 and DLX2; Western blot; colony formation assay; EMT marker analysis in irradiated A549 and MDA-MB-231 cells PloS one Medium 26799321
2017 BMP signaling through the type I receptor ALK-2 (ACVR1) induces DLX2 expression in glioma-initiating cells; DLX2 promotes apoptosis and neural differentiation of GICs, and valproic acid induces BMP2/4, ACVR1 and DLX2 expression with concomitant Smad1/5 phosphorylation. Silencing of ALK-2 and DLX2 by siRNA; mouse orthotopic transplantation model; Western blot for Smad1/5 phosphorylation; VPA treatment Oncogene Medium 28459464
2020 DLX2 directly binds to the WNT1 promoter (confirmed by ChIP assay) and activates Wnt/β-catenin signaling, which in turn promotes osteogenic differentiation of hBMSCs; pharmacological inhibition of β-catenin (FH535) abolishes the enhanced osteogenic capability induced by DLX2. ChIP assay; luciferase reporter; Western blot; ALP assay; Alizarin red staining; FH535 inhibitor Gene Medium 32165291
2018 DLX2 overexpression in chondrocytes inhibits MMP13 expression by directly binding to two Dlx2-response elements in the MMP13 promoter, resulting in increased accumulation of type II collagen and aggrecan (markers of early chondrocyte differentiation). Luciferase reporter assay; ChIP assay; overexpression in TMC23 chondroblasts; RT-PCR; Western blot Biochemical and biophysical research communications High 29787757
2017 Mutant Runx2 induces miR-185-5p expression, which directly targets and suppresses DLX2 (confirmed by dual-luciferase reporter assay with DLX2 3'-UTR); DLX2 suppression by miR-185-5p impairs amelogenesis and osteogenesis. miRNA microarray; dual-luciferase reporter assay; RT-PCR; Western blot; mutagenesis in LS8 and MC3T3-E1 cells Cell death & disease Medium 29242628
2023 JMJD3 demethylase promotes DLX2 expression by removing H3K27me3 repressive marks at the DLX2 locus; JMJD3 depletion phenocopies DLX2 loss in vascular smooth muscle cells (reduced proliferation, promoted apoptosis, altered collagen/MMP expression), and DLX2 overexpression in JMJD3-depleted cells restores intracranial aneurysm progression. JMJD3 knockdown; DLX2 overexpression/knockdown in HA-VSMCs; H3K27me3 ChIP; in vivo aneurysm model The Tohoku journal of experimental medicine Medium 37286519
1997 Antisense oligonucleotide-mediated knockdown of Dlx-2 (but not Dlx-1) in primary cultures of embryonic basal ganglia decreases MAP2 expression, reduces dendrite outgrowth, and increases cell proliferation, demonstrating that the Dlx-2 gene product regulates neuronal exit from the mitotic cycle and the capability to grow MAP2-positive dendrites. Antisense oligonucleotides against Dlx-2 in primary basal ganglia cultures; MAP2 and neurofilament immunostaining; BrdU proliferation assay Journal of molecular neuroscience Medium 9188040
2026 DLX2 functions as a pioneer transcription factor, forming a complex with LAP2α through a 38-amino-acid homeodomain motif, interacting with nucleosomes to promote chromatin remodeling and activate a pro-craniofacial ectomesenchymal gene network; disrupting DLX2-LAP2α interaction or silencing Dlx2 targets markedly diminishes ectomesenchymal differentiation from ESCs. Co-immunoprecipitation of DLX2-LAP2α complex; domain mutagenesis (38-aa homeodomain motif deletion); chromatin remodeling assays; ESC differentiation; CUT&Tag Science advances High 41533791
2025 DLX2 controls neural cell fate determination in the ventral telencephalon by directly repressing Notch signaling genes and glial fate-promoting transcription factors, thereby inhibiting early oligodendroglial differentiation during neurogenesis; single-cell spatial transcriptomics identified a secondary proliferative zone in the ventral SVZ regulated by DLX2-Notch axis. Single-cell whole-genome spatial transcriptomics; multi-omic approach; DLX2 gain/loss-of-function; Notch pathway gene expression analysis bioRxivpreprint Medium

Source papers

Stage 0 corpus · 94 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2000 Pallial and subpallial derivatives in the embryonic chick and mouse telencephalon, traced by the expression of the genes Dlx-2, Emx-1, Nkx-2.1, Pax-6, and Tbr-1. The Journal of comparative neurology 759 10906711
2006 The Evf-2 noncoding RNA is transcribed from the Dlx-5/6 ultraconserved region and functions as a Dlx-2 transcriptional coactivator. Genes & development 573 16705037
1993 Spatially restricted expression of Dlx-1, Dlx-2 (Tes-1), Gbx-2, and Wnt-3 in the embryonic day 12.5 mouse forebrain defines potential transverse and longitudinal segmental boundaries. The Journal of neuroscience : the official journal of the Society for Neuroscience 523 7687285
1997 Mutations of the homeobox genes Dlx-1 and Dlx-2 disrupt the striatal subventricular zone and differentiation of late born striatal neurons. Neuron 443 9247261
1997 Role of the Dlx homeobox genes in proximodistal patterning of the branchial arches: mutations of Dlx-1, Dlx-2, and Dlx-1 and -2 alter morphogenesis of proximal skeletal and soft tissue structures derived from the first and second arches. Developmental biology 388 9187081
1995 Null mutation of Dlx-2 results in abnormal morphogenesis of proximal first and second branchial arch derivatives and abnormal differentiation in the forebrain. Genes & development 321 7590232
2007 Dlx1 and Dlx2 control neuronal versus oligodendroglial cell fate acquisition in the developing forebrain. Neuron 293 17678855
1999 DLX-1, DLX-2, and DLX-5 expression define distinct stages of basal forebrain differentiation. The Journal of comparative neurology 238 10516593
1994 Differential and overlapping expression domains of Dlx-2 and Dlx-3 suggest distinct roles for Distal-less homeobox genes in craniofacial development. Mechanisms of development 217 7893603
1997 Role of Dlx-1 and Dlx-2 genes in patterning of the murine dentition. Development (Cambridge, England) 195 9428417
1993 The mouse Dlx-2 (Tes-1) gene is expressed in spatially restricted domains of the forebrain, face and limbs in midgestation mouse embryos. Mechanisms of development 194 8098616
1994 DLX-2, MASH-1, and MAP-2 expression and bromodeoxyuridine incorporation define molecularly distinct cell populations in the embryonic mouse forebrain. The Journal of neuroscience : the official journal of the Society for Neuroscience 185 7965042
2008 A dlx2- and pax6-dependent transcriptional code for periglomerular neuron specification in the adult olfactory bulb. The Journal of neuroscience : the official journal of the Society for Neuroscience 164 18562615
2008 Arx is a direct target of Dlx2 and thereby contributes to the tangential migration of GABAergic interneurons. The Journal of neuroscience : the official journal of the Society for Neuroscience 119 18923043
2002 Subpallial dlx2-expressing cells give rise to astrocytes and oligodendrocytes in the cerebral cortex and white matter. The Journal of neuroscience : the official journal of the Society for Neuroscience 93 12427838
2008 Generation of Cre-transgenic mice using Dlx1/Dlx2 enhancers and their characterization in GABAergic interneurons. Molecular and cellular neurosciences 89 19026749
2007 Distinct cis-regulatory elements from the Dlx1/Dlx2 locus mark different progenitor cell populations in the ganglionic eminences and different subtypes of adult cortical interneurons. The Journal of neuroscience : the official journal of the Society for Neuroscience 87 17494687
2000 Independent regulation of Dlx2 expression in the epithelium and mesenchyme of the first branchial arch. Development (Cambridge, England) 86 10603340
2019 Overexpression of Dlx2 enhances osteogenic differentiation of BMSCs and MC3T3-E1 cells via direct upregulation of Osteocalcin and Alp. International journal of oral science 73 30880332
2018 Dlx1 and Dlx2 Promote Interneuron GABA Synthesis, Synaptogenesis, and Dendritogenesis. Cerebral cortex (New York, N.Y. : 1991) 71 29028947
1996 Sequence, organization, and transcription of the Dlx-1 and Dlx-2 locus. Genomics 71 8812481
2016 Dlx-2 and glutaminase upregulate epithelial-mesenchymal transition and glycolytic switch. Oncotarget 68 26771232
2004 Dlx1 and Dlx2 function is necessary for terminal differentiation and survival of late-born retinal ganglion cells in the developing mouse retina. Development (Cambridge, England) 67 15604100
2001 Antagonistic regulation of Dlx2 expression by PITX2 and Msx2: implications for tooth development. Gene expression 62 11763998
2011 Transcription factor Dlx2 protects from TGFβ-induced cell-cycle arrest and apoptosis. The EMBO journal 55 21897365
2001 A zebrafish forebrain-specific zinc finger gene can induce ectopic dlx2 and dlx6 expression. Developmental biology 43 11180958
2001 Bone morphogenetic protein-2 (BMP-2) signaling to the Col2alpha1 gene in chondroblasts requires the homeobox gene Dlx-2. DNA and cell biology 43 11445007
1995 Regionalization of the developing forebrain: a comparison of FORSE-1, Dlx-2, and BF-1. The Journal of neuroscience : the official journal of the Society for Neuroscience 42 7869122
2012 The Rb/E2F pathway modulates neurogenesis through direct regulation of the Dlx1/Dlx2 bigene cluster. The Journal of neuroscience : the official journal of the Society for Neuroscience 41 22699903
2004 Cloning and developmental expression patterns of Dlx2, Lhx7 and Lhx9 in the medaka fish (Oryzias latipes). Mechanisms of development 41 15210202
2017 Mutant Runx2 regulates amelogenesis and osteogenesis through a miR-185-5p-Dlx2 axis. Cell death & disease 40 29242628
2010 Mutually exclusive expression of DLX2 and DLX5/6 is associated with the metastatic potential of the human breast cancer cell line MDA-MB-231. BMC cancer 40 21108812
2003 Dlx2 progenitor migration in wild type and Nkx2.1 mutant telencephalon. Cerebral cortex (New York, N.Y. : 1991) 39 12902388
2009 Interaction between DLX2 and EGFR regulates proliferation and neurogenesis of SVZ precursors. Molecular and cellular neurosciences 38 19683576
2016 KI67 and DLX2 predict increased risk of metastasis formation in prostate cancer-a targeted molecular approach. British journal of cancer 37 27336609
2020 Long non-coding RNA TUG1 promotes cell progression in hepatocellular carcinoma via regulating miR-216b-5p/DLX2 axis. Cancer cell international 35 31920462
1992 DLX2 (TES1), a homeobox gene of the Distal-less family, assigned to conserved regions on human and mouse chromosomes 2. Genomics 35 1354641
2015 Dlx-2 is implicated in TGF-β- and Wnt-induced epithelial-mesenchymal, glycolytic switch, and mitochondrial repression by Snail activation. International journal of oncology 34 25651912
2006 OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. International journal of oncology 34 16964386
2020 ASCL1- and DLX2-induced GABAergic neurons from hiPSC-derived NPCs. Journal of neuroscience methods 33 32065989
2017 Bone morphogenetic protein signaling mediated by ALK-2 and DLX2 regulates apoptosis in glioma-initiating cells. Oncogene 33 28459464
2012 Dynamic expression of the pro-dopaminergic transcription factors Pax6 and Dlx2 during postnatal olfactory bulb neurogenesis. Frontiers in cellular neuroscience 33 22371698
2000 Biomineralization, life-time of odontogenic cells and differential expression of the two homeobox genes MSX-1 and DLX-2 in transgenic mice. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 32 10750557
2017 Regulation of Brn3b by DLX1 and DLX2 is required for retinal ganglion cell differentiation in the vertebrate retina. Development (Cambridge, England) 28 28356311
2005 Dlx2 over-expression regulates cell adhesion and mesenchymal condensation in ectomesenchyme. Developmental biology 28 15848386
1995 The spatial localization of Dlx-2 during tooth development. Connective tissue research 28 7554927
2016 Smad2/3-Regulated Expression of DLX2 Is Associated with Radiation-Induced Epithelial-Mesenchymal Transition and Radioresistance of A549 and MDA-MB-231 Human Cancer Cell Lines. PloS one 27 26799321
2013 Increased expression of DLX2 correlates with advanced stage of gastric adenocarcinoma. World journal of gastroenterology 26 23674878
2006 Functional interactions between Dlx2 and lymphoid enhancer factor regulate Msx2. Nucleic acids research 26 17068080
2003 Dlx-1 and Dlx-2 expression in the adult mouse brain: relationship to dopaminergic phenotypic regulation. The Journal of comparative neurology 26 12722102
2010 Role of Dlx genes in craniofacial morphogenesis: Dlx2 influences skeletal patterning by inducing ectomesenchymal aggregation in ovo. Evolution & development 24 20883215
2020 Knockdown of circ_HIPK3 inhibits tumorigenesis of hepatocellular carcinoma via the miR-582-3p/DLX2 axis. Biochemical and biophysical research communications 23 32977948
2011 Homeobox gene Dlx-2 is implicated in metabolic stress-induced necrosis. Molecular cancer 23 21917150
2012 The effect of overexpression of Dlx2 on the migration, proliferation and osteogenic differentiation of cranial neural crest stem cells. Biomaterials 22 23246068
2016 A gain-of-function senescence bypass screen identifies the homeobox transcription factor DLX2 as a regulator of ATM-p53 signaling. Genes & development 21 26833729
2013 Cancer testis antigen OY-TES-1 expression and serum immunogenicity in colorectal cancer: its relationship to clinicopathological parameters. International journal of clinical and experimental pathology 21 24294369
2021 Direct reprogramming of oligodendrocyte precursor cells into GABAergic inhibitory neurons by a single homeodomain transcription factor Dlx2. Scientific reports 19 33574458
2020 DLX2 activates Wnt1 transcription and mediates Wnt/β-catenin signal to promote osteogenic differentiation of hBMSCs. Gene 19 32165291
2019 Actinidia Chinensis Planch Root extract attenuates proliferation and metastasis of hepatocellular carcinoma by inhibiting the DLX2/TARBP2/JNK/AKT pathway. Journal of ethnopharmacology 19 31891797
2007 GAD isoforms exhibit distinct spatiotemporal expression patterns in the developing mouse lens: correlation with Dlx2 and Dlx5. Developmental dynamics : an official publication of the American Association of Anatomists 19 17969168
2007 Dlx2 homeobox gene transcriptional regulation of Trkb neurotrophin receptor expression during mouse retinal development. Nucleic acids research 19 18086710
2019 Expression of ventral telencephalon transcription factors ASCL1 and DLX2 in the early fetal human cerebral cortex. Journal of anatomy 18 30861584
2011 Up-regulation of homeodomain genes, DLX1 and DLX2, by FLT3 signaling. Haematologica 18 21357706
2004 Identification and characterization of a novel transcript down-regulated in Dlx1/Dlx2 and up-regulated in Pax6 mutant telencephalon. Developmental dynamics : an official publication of the American Association of Anatomists 18 15376329
2005 Identification of an HLA-A24-restricted OY-TES-1 epitope recognized by cytotoxic T-cells. Microbiology and immunology 17 16301813
2012 Knockdown of OY-TES-1 by RNAi causes cell cycle arrest and migration decrease in bone marrow-derived mesenchymal stem cells. Cell biology international 16 22651134
1997 Dlx-2 homeobox gene controls neuronal differentiation in primary cultures of developing basal ganglia. Journal of molecular neuroscience : MN 16 9188040
1993 The human brain homeogene, DLX-2: cDNA sequence and alignment with the murine homologue. Gene 16 7901126
2015 Down-regulation of cancer/testis antigen OY-TES-1 attenuates malignant behaviors of hepatocellular carcinoma cells in vitro. International journal of clinical and experimental pathology 15 26339343
2017 Serum immunoreactivity of cancer/testis antigen OY-TES-1 and its tissues expression in glioma. Oncology letters 14 28529561
2018 Dlx2 overexpression enhanced accumulation of type II collagen and aggrecan by inhibiting MMP13 expression in mice chondrocytes. Biochemical and biophysical research communications 13 29787757
2022 LncRNA HOTTIP facilitates osteogenic differentiation in bone marrow mesenchymal stem cells and induces angiogenesis via interacting with TAF15 to stabilize DLX2. Experimental cell research 12 35644412
2011 Proneural transcription factors Dlx2 and Pax6 are altered in adult SVZ neural precursor cells following striatal cell loss. Molecular and cellular neurosciences 12 21397028
2021 Repeated Irradiation with γ-Ray Induces Cancer Stemness through TGF-β-DLX2 Signaling in the A549 Human Lung Cancer Cell Line. International journal of molecular sciences 11 33924205
2015 Effects of DLX2 overexpression on the osteogenic differentiation of MC3T3-E1 cells. Experimental and therapeutic medicine 10 26136955
2020 Cancer-testis Antigen OY-TES-1 Expression and Immunogenicity in Hepatocellular Carcinoma. Current medical science 9 32862383
2017 Dental and periodontal phenotypes of Dlx2 overexpression in mice. Molecular medicine reports 7 28447749
2024 Efficient Dlx2-mediated astrocyte-to-neuron conversion and inhibition of neuroinflammation by NeuroD1. Developmental neurobiology 6 39034481
2023 GABAergic neurons differentiated from BDNF- and Dlx2-modified neural stem cells restore disrupted neural circuits in brainstem stroke. Stem cell research & therapy 6 37365654
2022 A Neural Crest-specific Overexpression Mouse Model Reveals the Transcriptional Regulatory Effects of Dlx2 During Maxillary Process Development. Frontiers in physiology 6 35514355
2024 Osteocyte-derived exosomes regulate the DLX2/wnt pathway to alleviate osteoarthritis by mediating cartilage repair. Autoimmunity 5 38946534
2022 TES-1/Tes and ZYX-1/Zyxin protect junctional actin networks under tension during epidermal morphogenesis in the C. elegans embryo. Current biology : CB 5 36384139
2024 Characteristic changes in astrocyte properties during astrocyte-to-neuron conversion induced by NeuroD1/Ascl1/Dlx2. Neural regeneration research 4 39104117
2023 JMJD3 is Involved in Intracranial Aneurysm Development by Regulating DLX2 Expression through H3K27me3 Modification. The Tohoku journal of experimental medicine 2 37286519
2016 Overexpression of Dlx2 leads to postnatal condyle degradation. Molecular medicine reports 2 27315306
1999 Establishment and characterization of human immature teratoma cell line (TES-1). Anticancer research 2 10470137
2023 Effects of Dlx2 overexpression on the genes associated with the maxillary process in the early mouse embryo. Frontiers in genetics 1 36891149
2022 Immunohistochemistry Study of OY-TES-1 Location in Fetal and Adult Human Tissues. Journal of healthcare engineering 1 35463688
2026 DLX2 acts as a pioneer factor and drives Msx1+ ectomesenchyme formation from embryonic stem cells. Science advances 0 41533791
2026 DLX2 marks an immunosuppressive dendritic-cell program that reshapes cytotoxic immunity and marks a tolerogenic microenvironment in lung adenocarcinoma. Discover oncology 0 41761000
2025 DLX2 promotes gastric cancer epithelial- mesenchymal transition and malignant progression through the PI3K/AKT signaling pathway. Frontiers in oncology 0 41244921
2025 OY-TES-1 Splice Variant V5a in Glioma: A Driver of Malignancy and Potential Therapeutic Target. Current medical science 0 41428155
2011 Dlx2 over-expression: a possible mechanism for first branchial arch malformation. Shanghai kou qiang yi xue = Shanghai journal of stomatology 0 21779750
2003 [Expression of homeobox gene Msx-1, Msx-2 and Dlx-2 during murine mandibular first molar development]. Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology 0 14703475